ALNY vs SOLS · P/E 76, rev $1.29B vs P/E 71, rev $3.89B
Alnylam Pharmaceuticals Inc (ALNY) versus Solstice Advanced Materials, Inc (SOLS) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Solstice Advanced Materials, Inc (SOLS) is a specialty chemicals company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported SOLS revenue for 2025-12-31 was $3.89B. Net income was $237.0M. Revenue was up 3.1% from 2024-12-31 to 2025-12-31. SOLS currently screens at market cap $13.51B and trailing P/E 71.5.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. SOLS currently screens at market cap $13.51B and trailing P/E 71.5.
Not investment advice. Open the ALNY and SOLS stock pages for the full models.
Not investment advice.